Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2002 Jun 28;16(4):202–208. doi: 10.1002/jcla.10042

Human immunodeficiency virus genotype and hypertriglyceridemia

Soni J Anderson 1,✉, John F Bradley 1, Andrea Ferreira‐Gonzalez 1, Carleton T Garrett 1
PMCID: PMC6808024  PMID: 12112393

Abstract

Many HIV patients develop a progressive syndrome of abnormal body fat distribution accompanied by hypertriglyceridemia. Antiretroviral agents are thought to be etiologic in the syndrome, often termed “highly active antiretroviral therapy (HAART)‐associated lipodystrophy.” In the course of clinical HIV genotype testing, we observed that our HIV patients with hypertriglyceridemia had viral genotypes that were more highly mutated than those of our therapy‐matched control patients. Hypertriglyceridemia was statistically associated with predicted resistance for three nucleoside reverse transcriptase inhibitors: zidovudine, abacavir, and stavudine. Statistical analysis of 51 patients in retrospect revealed a strong association of mutations at reverse transcriptase codons M41 and T215 with hypertriglyceridemia (chi‐square (χ2) = 8.375, P=.0038; and χ2=7.445, P=.0064, respectively). This was in contrast to silent mutations, which occurred at equivalent rates in retroviral genotypes of patients with and without hypertriglyceridemia. The findings imply that the HIV genotype itself may be a significant etiologic factor in antiretroviral‐associated lipodystrophy. © 2002 Wiley‐Liss, Inc.

Keywords: lipodystrophy, HAART, resistance, mutation, reverse transcriptase, protease inhibitor, nucleoside analog

REFERENCES

  • 1. Anderson SJ, Anderson FP, McPherson RA. Antiviral therapy‐associated lipodystrophy syndrome. Clin Chem 2000;40:68–82. [Google Scholar]
  • 2. Boufassa F, Dulioust A, Lascaux AS. Lipodystrophy in 685 HIV‐1 treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2001;2:339–345. [DOI] [PubMed] [Google Scholar]
  • 3. Thiebaut R, Dequae‐Mechadou L, Ekouevi DK. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996–99. HIV Med 2001;2:84–88. [DOI] [PubMed] [Google Scholar]
  • 4. Pernerstorfer‐Schoen H, Jilma B, Perschler A. Sex differences in HAART‐associated dyslipidaemia. AIDS 2001;15:725–734. [DOI] [PubMed] [Google Scholar]
  • 5. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transmit Infect 2001;77:158–173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Mercie P, Tchamgoue S, Thiebaut R. Atherogenic lipid profile in HIV‐1‐infected patients with lipodystrophy syndrome. Eur J Intern Med 2000;11:257–263. [DOI] [PubMed] [Google Scholar]
  • 7. Fauvel J, Bonnet E, Ruidavets JB. An interaction between apo C‐III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15:2397–2406. [DOI] [PubMed] [Google Scholar]
  • 8. Miserez AR, Muller PY, Barella L. A single nucleotide polymorphism in the sterol regulatory element binding protein 1c gene is predictive of HIV related hyperlipoproteinaemia. AIDS 2001;15:2045–2049. [DOI] [PubMed] [Google Scholar]
  • 9. Duong M, Petit JM, Piroth L. Association between insulin resistance and hepatitis C virus chronic infection in HIV‐hepatitis C virus‐coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:245–250. [DOI] [PubMed] [Google Scholar]
  • 10. Berthold HK, Parhofer KG, Ritter MM. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;246:567–575. [DOI] [PubMed] [Google Scholar]
  • 11. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 2001;42:181–188. [DOI] [PubMed] [Google Scholar]
  • 12. Hatano H, Miller KD, Yoder CP. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000;14:1935–1942. [DOI] [PubMed] [Google Scholar]
  • 13. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez‐Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV‐infected subjects under long‐term successful triple combination therapy. AIDS 2000;14:807–812. [DOI] [PubMed] [Google Scholar]
  • 14. Purnell JQ, Zambon A, Knopp RH. Effect of ritonavir on lipids and post‐heparin lipase activities in normal subjects. AIDS 2000;14:51–57. [DOI] [PubMed] [Google Scholar]
  • 15. Galli M, Ridolfo AL, Adorni F. Body habitus changes and metabolic alterations in protease inhibitor‐naive HIV‐1‐infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:21–31. [DOI] [PubMed] [Google Scholar]
  • 16. Saint‐Marc T, Partisani M, Poizot‐Martin I. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long‐term nucleoside analogue therapy. AIDS 1999;13:1659–1667. [DOI] [PubMed] [Google Scholar]
  • 17. van der Valk M, Gisolf EH, Reiss P. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV‐1 infection. AIDS 2001;15:847–855. [DOI] [PubMed] [Google Scholar]
  • 18. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV‐infected population: it all depends on the definition. HIV Med 2001;2:174–180. [DOI] [PubMed] [Google Scholar]
  • 19. Lichtenstein KA, Ward DJ, Moorman AC. Clinical assessment of HIV‐associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389–1398. [DOI] [PubMed] [Google Scholar]
  • 20. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre‐AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000;14:1829–1837. [DOI] [PubMed] [Google Scholar]
  • 21. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27–31. [DOI] [PubMed] [Google Scholar]
  • 22. Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS‐related complex. Lancet 1992;339:453–456. [DOI] [PubMed] [Google Scholar]
  • 23. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor‐alpha T‐cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodficiency virus‐associated lipodystrophy syndrome. Blood 2000;95:3191–3198. [PubMed] [Google Scholar]
  • 24. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV‐1 reverse transcriptase: implications for drug resistance. Science 1998;282:1669–1675. [DOI] [PubMed] [Google Scholar]
  • 25. Hance AJ, Lemiale V, Izopet J. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001;75:6410–6417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Devereux HL, Emery VC, Johnson MA, Loveday C. Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations. J Med Virol 2001;65:218–224. [DOI] [PubMed] [Google Scholar]
  • 27. Kaufmann D, Munoz M, Bleiber G. Virological and immunological characteristics of HIV treatment failure. AIDS 2000;14:1767–1774. [DOI] [PubMed] [Google Scholar]
  • 28. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 2002;41:27–65. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES